Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ana Beatriz Korngold"'
Autor:
Ana Beatriz Korngold, Michelle Hotard, Priya Balasubramanian, Phillip Eckels, Tom Spencer, Drew C. Deniger, Matthew R. Collinson-Pautz, Ugochi Ibekwe, Lin-Kin Yong, Thomas Hunt, Frances Adeyemi, Cathy Wang, Jourdan Andersson, Yaoyao Shi, Lenka V. Hurton, Elizabeth Figueroa, Haroon Hashmi, Mariam Khalil, Kelly O’Brien, Lauren Heese, Alena A Chekmasova, Emarco Olivares, Raffaele Baffa, David Torres, Eleanor De Groot, Julissa Simmons, Tegan Markus, Geraldine Bardelli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundEGFR, KRAS and TP53 have frequent somatic hotspot mutations giving rise to biologically relevant amino acid substitutions in EGFR, KRAS and p53 proteins, respectively, that can be processed and presented on the cell surface by human leukocy
Autor:
Ana Beatriz Korngold, Matthew R. Collinson-Pautz, Ming Zhang, Laurence J.N. Cooper, Lin-Kin Yong, Drew C. Deniger, Eleanor De Groot, Yaoyao Shi, Ugochi Ibekwe, Julissa Simmons, Lenka V. Hurton
Publikováno v:
Cancer Research. 81:1515-1515
Mutations in critical genes for cell survival and proliferation, e.g., KRAS and TP53, are found as clonal events in multiple tumor types of unrelated people likely due to their importance to the malignant phenotype. T cells recognize products of muta
Autor:
David H. Spencer, Mirjam H.M. Heemskerk, MyLinh Duong, David Torres, Jeannette Crisostomo, J.H. Frederik Falkenburg, Tsvetelina Pentcheva-Hoang, Tania Veliz Rodriguez, J. Henri Bayle, Aaron E. Foster, Kevin M. Slawin, Ana Beatriz Korngold, Matthew R. Collinson-Pautz, Annemarie Moseley
Publikováno v:
Cancer Research. 77:3745-3745
T cells engineered to express the α and β chains of antigen-specific T cell receptors (TCRs) have shown promise as a cancer immunotherapy treatment; however, durable responses have been limited by poor persistence of gene-modified T cells. Addition
Autor:
Tania Veliz Rodriguez, An Lu, Kevin M. Slawin, Tsvetelina Pentcheva-Hoang, Lorenz Jahn, Annemarie Moseley, Ana Beatriz Korngold, Jeannette Crisostomo, David Torres, Mirjam H.M. Heemskerk, David M. Spencer, Aaron E. Foster
Publikováno v:
Blood. 128:4550-4550
Introduction: Use of T cells engineered to express antigen-specific T cell receptors (TCRs) has shown promise as a cancer immunotherapy treatment; however, durable responses have been limited by poor T cell persistence and expansion in vivo. Addition
Autor:
Tania Veliz Rodriguez, Annemarie Moseley, Mirjam H.M. Heemskerk, Lorenz Jahn, Aaron E. Foster, David Torres, David H. Spencer, Ana Beatriz Korngold, Jeannette Crisostomo, Kevin M. Slawin, An Lu, Tsvetelina Pentcheva-Hoang
Publikováno v:
Cancer Immunology Research. 4:B078-B078
Introduction: Use of T cells engineered to express antigen-specific T cell receptors (TCRs) has shown promise as a cancer immunotherapy treatment; however, durable responses have been limited by poor T cell persistence and expansion in vivo. Addition
Autor:
Bipulendu Jena, Hiroaki Taguchi, Ana Beatriz Korngold, Laurence J.N. Cooper, Aleksandra Nowicka, Helen Huls
Publikováno v:
Cancer Immunology Research. 4:A179-A179
Success of T-cell based immunotherapy depends largely on exogenous modification and propagation of patient or donor derived T cells. The conventional paradigm is to stimulate primary T cells cross-linking endogenous CD3-complex with a monoclonal anti
Publikováno v:
Cancer Immunology Research. 4:B053-B053
Clinical data demonstrates that one chimeric antigen receptor (CAR) design targeting T cells to a given tumor-associated antigen (TAA) will have varying therapeutic potential in different patients. For example, second generation CD19-specific CARs ac